Dr. Goy on Novel Therapies at the JTCC Conference

Andre Goy, MD, MS
Published Online: Tuesday, Oct 11, 2011
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”

Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming New Frontiers In The Management of Solid and Liquid Tumors conference at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011.

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”

Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming New Frontiers In The Management of Solid and Liquid Tumors conference at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011.

Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-InflammationMay 31, 20161.5
Advances in Next-Generation Sequencing in Precision Oncology: Solid TumorsJul 27, 20162.0